About Ariad Pharmaceuticals (NASDAQ:ARIA)
ARIAD Pharmaceuticals, Inc. (ARIAD) is an oncology company. The Company is focused on transforming the lives of cancer patients with medicines. The Company's product pipeline includes Iclusig (ponatinib), brigatinib, AP32788 and ridaforolimus. The Company's Iclusig is a tyrosine kinase inhibitor (TKI) that is approved in the United States, the European Union, Australia, Switzerland, Israel and Canada for the treatment of adult patients with chronic myeloid leukemia (CML), and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Its Brigatinib is an investigational inhibitor of anaplastic lymphoma kinase (ALK). Its AP32788 is a TKI, which is designed as a targeted therapy for patients with non-small cell lung cancer (NSCLC) with specific mutations in two kinases, epidermal growth factor receptor (EGFR), or human epidermal growth factor receptor 2 (HER2). Its Ridaforolimus is an investigational inhibitor of the mammalian target of rapamycin (mTOR).
Industry, Sector and Symbol
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
EPS (Most Recent Fiscal Year)N/A
Return on EquityN/A
Return on Assets-17.16%
Ariad Pharmaceuticals (NASDAQ:ARIA) Frequently Asked Questions
What is Ariad Pharmaceuticals' stock symbol?
Ariad Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARIA."
How were Ariad Pharmaceuticals' earnings last quarter?
Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) posted its quarterly earnings data on Thursday, July, 28th. The pharmaceutical company reported $0.59 EPS for the quarter, beating the Zacks' consensus estimate of ($0.11) by $0.70. The pharmaceutical company had revenue of $65.30 million for the quarter, compared to the consensus estimate of $60.64 million. The company's revenue was up 133.0% compared to the same quarter last year. During the same quarter last year, the company earned ($0.28) earnings per share. View Ariad Pharmaceuticals' Earnings History.
Has Ariad Pharmaceuticals been receiving favorable news coverage?
News headlines about ARIA stock have been trending somewhat positive this week, Accern Sentiment reports. Accern rates the sentiment of news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Ariad Pharmaceuticals earned a news impact score of 0.12 on Accern's scale. They also gave news stories about the pharmaceutical company an impact score of 46.55 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.
How do I buy shares of Ariad Pharmaceuticals?
Shares of ARIA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Ariad Pharmaceuticals' stock price today?
One share of ARIA stock can currently be purchased for approximately $23.99.
How can I contact Ariad Pharmaceuticals?
Ariad Pharmaceuticals' mailing address is 125 Binney St, CAMBRIDGE, MA 02142-1123, United States. The pharmaceutical company can be reached via phone at +1-617-4940400.
MarketBeat Community Rating for Ariad Pharmaceuticals (ARIA)MarketBeat's community ratings are surveys of what our community members think about Ariad Pharmaceuticals and other stocks. Vote "Outperform" if you believe ARIA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARIA will underperform the S&P 500 over the long term. You may vote once every thirty days.